Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Pfizer and Bristol-Myers Squibb to present Eliquis data at ACC.16

Pfizer and Bristol-Myers Squibb to present Eliquis data at ACC.16

31st March 2016

Pfizer and Bristol-Myers Squibb will be attending the American College of Cardiology's 65th Annual Scientific Session (ACC.16), where they will share their latest Eliquis research data.

Running from April 2nd to 4th in Chicago, the conference will see the companies present a total of 17 abstracts, strengthening the body of evidence on the use of Eliquis to reduce the risk of stroke in patients with nonvalvular atrial fibrillation and for the treatment of patients with venous thromboembolism.

The safety and efficacy of the novel anticoagulant will be supported by evidence from the phase III ARISTOTLE and AMPLIFY clinical studies, as well as a number of retrospective analyses of real-world data.

Dr Rory O'Connor, senior vice-president and head of global medical affairs for Pfizer's innovative pharmaceuticals business, said: "Retrospective analyses of real-world data add an important component to our knowledge of Eliquis and may help to inform healthcare practitioners in their treatment decisions."

The drug functions by inhibiting Factor Xa, a key blood clotting protein, to help decrease thrombin generation and blood clot formation.ADNFCR-8000103-ID-801815641-ADNFCR

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.